Page last updated: 2024-12-05

tributyrin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tributyrin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tributyrin : A triglyceride obtained by formal acylation of the three hydroxy groups of glycerol by butyric acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6050
CHEMBL ID118722
CHEBI ID35020
SCHEMBL ID23825
MeSH IDM0047620

Synonyms (75)

Synonym
2,3-bis(butyryloxy)propyl butyrate
1,2,3-tributyrylglycerol
2,3-di(butanoyloxy)propyl butanoate
LS-14448
butanoic acid, 1,2,3-propanetriyl ester
NCI60_021427
tri-n-butyrin
butyric acid triester with glycerin
butyrin, tri-
glycerol tributanoate
fema no. 2223
tributyrinine
nsc 661583
brn 1714746
tributin
einecs 200-451-5
ai3-01776
glycerin tributyrate
butyrin
tributyryl glyceride
1,2,3-propanetriyl tributanoate
glyceroltributyrin
hsdb 878
tributyroin
tributyrl glyceride
butyryl triglyceride
60-01-5
nsc661583
1,3-tributyrylglycerol
glyceryl tributyrate
nsc-661583
tributyrin
inchi=1/c15h26o6/c1-4-7-13(16)19-10-12(21-15(18)9-6-3)11-20-14(17)8-5-2/h12h,4-11h2,1-3h
tributyrin, 97%, fg
glyceryl tributyrate, >=99%
glycerol tributyrate
CHEMBL118722
chebi:35020 ,
T0364
unii-s05lz624mf
s05lz624mf ,
4-02-00-00799 (beilstein handbook reference)
AKOS015903304
tributyrin [fcc]
tributyrin [mi]
glyceryl tri-butyrate
tributyrin [hsdb]
tributyrin [who-dd]
glycerol tributyrate [fhfi]
SCHEMBL23825
1,2,3-tributanoylglycerol
propane-1,2,3-triyl tributanoate
1,2,3-propanetriol, tributyrate
propane-1,2,3-triyl tributyrate
2,3-bis(butyryloxy)propyl butyrate #
dtxsid4052267 ,
tox21_303991
dtxcid90818116
NCGC00357211-01
cas-60-01-5
glyceryl tributyrate, analytical standard
glyceryl tributyrate, puriss., >=98.5% (gc)
glyceryl tributyrate, technical, >=94.0% (gc)
mfcd00009392
CS-W012120
kodaflex
tri-butyrin
fema 2223
DB12709
Q4116129
bdbm50212744
S6263
HY-W011404
gtpl12450
F71241

Research Excerpts

Overview

Tributyrin (TB) is a butyric acid precursor and has a key role in anti-inflammatory and intestinal barrier repair effects. TributyrIn (TBU) has beneficial effects on the maintenance of normal intestinal morphology.

ExcerptReferenceRelevance
"Tributyrin (TB) is a butyric acid precursor and has a key role in anti-inflammatory and intestinal barrier repair effects by slowly releasing butyric acid. "( Tributyrin alleviates gut microbiota dysbiosis to repair intestinal damage in antibiotic-treated mice.
Chen, Z; Han, Y; Lan, T; Li, H; Ma, X; Song, Y; Tao, M; Wang, C; Xu, Z; Yang, N; Zhao, H, 2023
)
3.8
"Tributyrin (TBU) is a good dietary source of butyrate and has beneficial effects on the maintenance of normal intestinal morphology. "( Dietary supplementation with tributyrin alleviates intestinal injury in piglets challenged with intrarectal administration of acetic acid.
Chen, X; Ding, B; Gong, J; Hou, Y; Liu, Y; Wang, L; Wang, Q; Wu, G; Yi, D; Yin, Y; Zhu, H, 2014
)
2.14
"Tributyrin (TBT) is a TAG composed of three butyric acids that has beneficial effects on ulcerative colitis due to its trophic, anti-inflammatory, pro-apoptotic and anti-carcinogenic properties. "( Antioxidative and immunomodulatory effects of tributyrin supplementation on experimental colitis.
Alvarez-Leite, J; Batista, NV; Cara, DC; Cardoso, VN; Faria, AM; Ferreira, TR; Leonel, AJ; Oliveira, RP; Santiago, AF; Santos, RC; Teixeira, LG, 2013
)
2.09
"Tributyrin (TB) is a prodrug of butyrate known to induce tumor cells to differentiate. "( Tributyrin induces growth inhibitory and differentiating effects on HT-29 colon cancer cells in vitro.
Eckert, K; Maurer, HR; Schröder, C, 1998
)
3.19

Effects

ExcerptReferenceRelevance
"Tributyrin has been shown to be an effective antitumor agent alone or in combination with other chemotherapeutic agents in vitro. "( Preparation of tributyrin emulsion and characterization of the binding of the emulsion particles to low-density lipoprotein in vitro.
Ho, PC; Su, J, 2004
)
2.12

Actions

ExcerptReferenceRelevance
"Tributyrin could inhibit the growth of gastric cancer cells effectively in vitro by inhibiting DNA synthesis and inducing apoptosis, which was associated with the down-regulated Bcl-2 expression and the up-regulated Bax expression. "( Tributyrin inhibits human gastric cancer SGC-7901 cell growth by inducing apoptosis and DNA synthesis arrest.
Xu, YH; Yan, J, 2003
)
3.2

Treatment

Tributyrin-treated tumours showed the strongest effect with 38% apoptotic nuclei in the prostate cancer cell line PC3. Treatment increased binding of (OH)2D3 to its receptor 1.5-fold, without any change in receptor affinity.

ExcerptReferenceRelevance
"Tributyrin treatment in the nursery phase alone did not have a significant effect on muscle growth or feed efficiency."( Dietary tributyrin, an HDAC inhibitor, promotes muscle growth through enhanced terminal differentiation of satellite cells.
Grilli, E; Iwaniuk, M; Murray, RL; Stahl, CH; Zhang, W, 2018
)
1.64
"Tributyrin-treated tumours showed the strongest effect with 38% apoptotic nuclei in the prostate cancer cell line PC3."( Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer.
Altug, V; Genze, F; Gschwend, JE; Hautmann, RE; Hofer, MD; Kuefer, R; Kunzi-Rapp, K; Zorn, C, 2004
)
1.37
"Treatment with tributyrin resulted in lower HDAC activity and Hdac3 and Hdac4 gene expression, and an increase of histone H3 lysine 9 and 18 and histone H4 lysine 16 acetylation as compared with the experimental group 1."( The chemopreventive activity of the butyric acid prodrug tributyrin in experimental rat hepatocarcinogenesis is associated with p53 acetylation and activation of the p53 apoptotic signaling pathway.
Beland, FA; de Conti, A; Heidor, R; Koturbash, I; Kuroiwa-Trzmielina, J; Moreno, FS; Ong, TP; Pogribny, IP; Tryndyak, V, 2013
)
0.97
"Treatment with tributyrin emulsion suppressed the colony formation of melanoma cells in a dose-dependent manner."( Preparation and evaluation of tributyrin emulsion as a potent anti-cancer agent against melanoma.
Kang, SN; Lee, E; Lee, MK; Lim, SJ, 2011
)
1
"Treatment with tributyrin increased binding of (OH)2D3 to its receptor 1.5-fold, without any change in receptor affinity."( Tributyrin, a stable and rapidly absorbed prodrug of butyric acid, enhances antiproliferative effects of dihydroxycholecalciferol in human colon cancer cells.
Gaschott, T; Milovic, V; Stein, J; Steinhilber, D, 2001
)
2.09

Toxicity

ExcerptReferenceRelevance
"5, 8, 12 or 24 hours led to cumulative LD50 doses which were markedly higher than the acute one."( Toxicity of soman after repetitive injection of sublethal doses in guinea-pig and mouse.
Fonnum, F; Lyngaas, S; Sterri, SH, 1981
)
0.26

Pharmacokinetics

ExcerptReferenceRelevance
" After oral administration, maximal plasma concentration (C(max)), time to reach maximal plasma concentration (T(max)), and elimination half-life (T(1/2)) of butyrate were 87."( Evaluation of tributyrin lipid emulsion with affinity to low-density lipoprotein: pharmacokinetics in adult male Wistar rats and cellular activity on Caco-2 and HepG2 cell lines.
He, L; Ho, PC; Su, J; Zhang, N, 2006
)
0.69

Bioavailability

ExcerptReferenceRelevance
"Drug solubility and lymphatic transport enhancements are two main pathways to improve drug oral bioavailability for microemulsions."( Microemulsions containing long-chain oil ethyl oleate improve the oral bioavailability of piroxicam by increasing drug solubility and lymphatic transportation simultaneously.
Guo, Q; Hu, H; Li, P; Song, J; Wang, K; Wu, C; Xing, Q; Xu, D; You, X, 2016
)
0.43
" The present study demonstrates that, in broilers, effects of butyrate on digestive processes are conditioned by the GIT segment wherein the molecule is present and indicates its influence on digestive function and bioavailability of AA."( Butyrate presence in distinct gastrointestinal tract segments modifies differentially digestive processes and amino acid bioavailability in young broiler chickens.
Hendriks, WH; Kwakkel, RP; Moquet, PCA; Onrust, L; Salami, SA, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
"5-1 mM) were achieved, but butyrate disappeared from plasma by 5 h after dose, we are now pursuing dose escalation with dosing three times daily, beginning at a dose of 450 mg/kg/day."( Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
Conley, BA; Dover, G; Egorin, MJ; Fram, RJ; Rosen, DM; Sausville, EA; Tait, N; Van Echo, DA, 1998
)
0.54
"In mice, oral dosing with tributyrin resulted in detectable plasma butyrate concentrations as early as at 5 min after treatment and produced peak plasma butyrate concentrations at between 15 and 60 min after dosing."( Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats.
Egorin, MJ; Eiseman, JL; Plaisance, K; Sentz, DL; Yuan, ZM, 1999
)
0.81
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
EC 3.5.1.98 (histone deacetylase) inhibitorAn EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the function of histone deacetylase (EC 3.5.1.98).
protective agentSynthetic or natural substance which is given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
triglycerideAny glyceride resulting from the condensation of all three hydroxy groups of glycerol (propane-1,2,3-triol) with fatty acids.
butyrate esterAny carboxylic ester where the carboxylic acid component is butyric acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
triacylglycerol biosynthesis (Chlamydomonas)09
triacylglycerol degradation95
diacylglycerol and triacylglycerol biosynthesis812

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency17.80870.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency61.91230.001530.607315,848.9004AID1224841; AID1259401
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (315)

TimeframeStudies, This Drug (%)All Drugs %
pre-199048 (15.24)18.7374
1990's57 (18.10)18.2507
2000's89 (28.25)29.6817
2010's93 (29.52)24.3611
2020's28 (8.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.27 (24.57)
Research Supply Index5.81 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index105.83 (26.88)
Search Engine Supply Index3.96 (0.95)

This Compound (36.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (2.45%)5.53%
Reviews5 (1.53%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other313 (96.01%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]